Let’s Win Scientific Advisory Board Chair Dr. Allyson Ocean explains the surprising clinical trial results in pancreatic and rectal cancers.
Can targeted radiation disrupt tumor growth in the liver of advanced pancreatic cancer patients with BRCA2 and PALB2 mutations?
Dr. Tanios Bekaii-Saab reports promising results of the KRYSTAL-1 trial, which targets a KRAS mutation common to pancreatic cancer.
Researchers are testing a thyroid drug to see if it is effective against pancreatic neuroendocrine tumors, among other cancers.
Dr. Eugene Koay is leading a platform trial, for a more nimble way to adapt to participants’ response to treatments being tested.
Researchers are testing a new drug that better-allows chemotherapy to penetrate the tumor microenvironment of pancreatic cancer.
Dr. Elizabeth Jaffee explains the importance of Lustgarten’s Clinical Accelerator Initiative to speed up the time from bench to trial.
Dr. Philip Philip focuses on disrupting cancer cell metabolism with devimistat, now in a phase III global clinical trial.
CRISPR technology is used as part of an immunotherapy clinical trial for metastatic pancreatic cancer and other GI cancers.